November 7th Options Now Available For Moderna (MRNA)

Options analysis for Moderna (MRNA), trading at $25.26, highlights two strategies for yield enhancement or discounted entry. Selling a $25.00 strike put for $1.99 premium offers an effective cost basis of $23.01, with a 57% chance of expiring worthless and yielding 7.96% (67.50% annualized) on the cash commitment. Alternatively, a covered call strategy with a $26.00 strike, selling for $2.00 premium, could generate a 10.85% return if MRNA is called away or a 7.92% (67.14% annualized) premium if the option expires worthless (49% probability), noting implied volatilities (74-77%) are above MRNA's 66% trailing 12-month actual volatility.

Analysis

The options market for Moderna (MRNA), currently trading at $25.26, presents two distinct yield-enhancing strategies driven by elevated implied volatility. Selling a cash-secured put at the $25.00 strike for a $1.99 premium creates an effective cost basis of $23.01, representing a notable discount for investors intending to acquire the stock. This strategy has a 57% probability of the option expiring worthless, which would generate a 7.96% return on the cash commitment, equivalent to a 67.50% annualized yield. Alternatively, for existing shareholders, writing a covered call at the $26.00 strike for a $2.00 premium offers a potential total return of 10.85% if the stock is called away, while capping upside beyond that level. There is a 49% chance this call expires worthless, providing a 7.92% income boost (67.14% annualized). A critical factor underpinning the attractiveness of both strategies is the volatility spread; the implied volatility of the options (74-77%) is significantly higher than the stock's trailing twelve-month actual volatility of 66%, indicating that options are currently priced richly, benefiting option sellers.

Key Decisions for Investors

• Investors bullish on MRNA but seeking a better entry point could sell the $25.00 put to either acquire shares at an effective cost of $23.01 or earn a high-yield premium if the stock remains above the strike.
• Current MRNA shareholders with a neutral to moderately bullish outlook should consider the covered call strategy at the $26.00 strike to generate immediate income, but must be willing to forgo potential upside above that price.
• The significant premium of implied volatility (74-77%) over historical volatility (66%) suggests that option-selling strategies are currently favorable, allowing investors to capitalize on the market's expectation of future price swings.